Non-tumor portal thrombosis (PT) is a frequent complication of cirrhosis. Its treatment is essentially based on anticoagulation which, in a context of haemostasis disorders, can lead to bleeding complications.Moreover, it has not been proven that revascularization of the portal trunk has an impact on survival and on the evolution of the underlying liver disease.The objectives of this work were first to evaluate the prevalence, the risk factors and the clinical impact of PT in cirrhotic patients. Secondly, to discuss the interest of anti-coagulant treatment.